Liuhong Chen Email

VP, Discovery . Bicycle Therapeutics

Current Roles

Bicycle Therapeutics is pioneering first in class therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform. Bicycles are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis. Bicycle Therapeutics is rapidly advancing towards the clinic in 2017 in collaboration with Cancer Research UK (CRUK), with its lead programme using a Bicycle Drug Conjugate® to selectively deliver toxin to tumours. Bicycle is also exploring the potential of bicyclic peptides as targeted, titratable and rapidly penetrant immunomodulators, overcoming the challenges seen for other agents with long exposure, irreversible effects and attendant toxicities. The company is collaborating in oncology, as evidenced by the recently announced CRUK partnership, and in other areas, such as respiratory and cardiovascular and metabolic disease, through a significant new partnership with AstraZeneca, to realise the full therapeutic potential of the Bicycle technology.
Bicycle Therapeutics Address
35 Cambridgepark Drive
Lexington, MA
United States
Bicycle Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.